Zanidatamab regimens improve survival for gastroesophageal cancer
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...
Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...
A dual-center study shows that a deep learning radiomics model applied to routine mammograms can noninvasively predict HER2-positive and HER2-low breast cancer status, offering a p...
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...
The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.